Response to: Neuromelanin? T 1 shortening is a necessary condition
Brain Communications · 2026-05-05 · 8 (3)
DOI: 10.1093/braincomms/fcag215 ↗At a glance
Leserbrief in Brain Communications, published online on 2026-06-09. Written by Jean-Baptiste Pérot and 3 co-authors. Institution: Paris Brain Institute-ICM, MOVIT team, Sorbonne Université, Inserm U1127, CNRS 7225, Hôpital Pitié-Salpêtriere, Paris 75013, France. 11 references. The full text is freely available (open access, CC BY 4.0). Funded by: EU Joint Programme Neurodegenerative Disease Research, NIPARK.
Abstract (original language)
Santrauka nepasiekiama.
Authors and institutions
- Paris Brain Institute-ICM, MOVIT team, Sorbonne Université, Inserm U1127, CNRS 7225, Hôpital Pitié-Salpêtriere, Paris 75013, France.
- Department of Radiology, Lausanne University Hospital (CHUV), Lausanne 1011, Switzerland.
- Neurodegenerative Diseases Research Group, Vall D'Hebron Research Institute (VHIR)-Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Barcelona 08035, Spain.
- Department Malalties Neurodegeneratives, Catalan Institution for Research and Advanced Studies (ICREA), Barcelona 08036, Spain.
ORCID profiles: Jean-Baptiste Pérot, Miquel Vila
Funding
- EU Joint Programme Neurodegenerative Disease Research
- NIPARK
Cite
APA
Pérot, J. B., Gonzalez-Sepulveda, M., Vila, M., & Lehéricy, S. (2026). Response to: Neuromelanin? T 1 shortening is a necessary condition. Brain Communications, 8(3). https://doi.org/10.1093/braincomms/fcag215
Vancouver
Pérot JB, Gonzalez-Sepulveda M, Vila M, Lehéricy S. Response to: Neuromelanin? T 1 shortening is a necessary condition. Brain Communications. 2026;8(3). doi:10.1093/braincomms/fcag215
BibTeX
@article{Prot2026,
author = {Pérot, Jean-Baptiste and Gonzalez-Sepulveda, Marta and Vila, Miquel and Lehéricy, Stéphane},
title = {Response to: Neuromelanin? T 1 shortening is a necessary condition},
journal = {Brain Communications},
year = {2026},
volume = {8},
number = {3},
doi = {10.1093/braincomms/fcag215}
}
EUVIMED